UVR

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Retrieved on: 
星期三, 三月 6, 2024
Lentigo, Pigment, Metabolism, Melasma, Elasticity, UVR, Ageing, Patent, Phio Pharmaceuticals, Skin, Hyperpigmentation, Gene silencing, TYR, Downregulation and upregulation, Iodosobenzene, MMP1, Vaccine

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.

Key Points: 
  • The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.
  • Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis.
  • “We have a robust patent portfolio for Phio’s INTASYL siRNA technology,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
  • “The addition of this recent patent grant for treatment of photodamaged skin is complementary to our current initiative in treating skin cancer.”